NCI Launches First-Ever Study to Determine if Biomarkers Can Help Guide Treatment for Lung Cancer

National Institutes of Health: News and Events, Oct 2, 2008

This study, sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, is called MARVEL (Marker Validation for Erlotinib in Lung Cancer) and will attempt to definitively establish the future value of selecting patients for treatment based on the presence or absence of EGFR activation.

To read the full text of this article, click here: http://www.nih.gov/news/health/oct2008/nci-02.htm